Rhonda Voskuhl, MD, University of California, Los Angeles, CA, shares her thoughts on where the greatest developments in the multiple sclerosis (MS) space will be in the coming years. Dr Voskuhl notes that while significant progress has been achieved using anti-inflammatory agents, a greater focus on neuroregeneration is needed. MS now has over 15 approved drugs that can effectively prevent relapses, but an unmet need in the field is therapies for progressive phase disease. Treatments are needed that can repair established damage in order to move the field forward. This interview took place during the ACTRIMS Forum 2021.